Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous

Hgb C Hemoglobinopathy Clinical Trial

Official title:

Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00481260
• Other study ID #: 5100706.EMC
• Status: Completed
• Phase: N/A
• First received: May 31, 2007
• Last updated: September 3, 2009
• Start date: May 2007
• Est. completion date: December 2008

Study information

• Verified date: September 2009
• Source: HaEmek Medical Center, Israel
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Observational

Clinical Trial Summary

Hgb C is an hemoglobinopathy quite rare in Israel. The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups.

Also the characteristics of carriers and the incidence in northern Israel were a large arab population lives, was not study. The results of this study can be useful for screening purpose in a area were another hemoglobinopathies are frequent.

Description:

Hgb C is an hemoglobinopathy quite rare in Israel. The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups.

Also the characteristics of carriers and the incidence in northern Israel were a large arab population lives, was not study. The results of this study can be useful for screening purpose in a area were another hemoglobinopathies are frequent.

The study will record the clinical characteristics of the homozygous Hgb C patients and the hematology characteristics of all the heterozygous carriers detected in northern Israel

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: December 2008
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All patients diagnosed as homozygous for Hgb C disease or double heterozygous in combination to other abnormal hemoglobin, and all the carriers detected in the hematology laboratory during the screening for abnormal hemoglobins in northern Israel

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Hemoglobinopathies
• Hgb C Hemoglobinopathy

Intervention

Procedure:
• Medical history and basic laboratory analysis
Medical history and basic laboratory analysis

Locations

Country	Name	City	State
Israel	Pediatric Hematology Unit - HaEmek Medical Center	Afula

Sponsors (1)

Lead Sponsor	Collaborator
HaEmek Medical Center, Israel

Country where clinical trial is conducted

Israel,